What to do with $101M

Last week's $101M tranched series B round for oncology play Tesaro Inc. is expected to get the company to NDA submission for its lead candidate, in-license up to two additional compounds and advance a preclinical program into the clinic, David Mott of New Enterprise Associates told Ebb & Flow.

The offering is the largest biotech series B round since the $169.4 million for cancer company OncoMed Pharmaceuticals Inc. at the end of 2008...